Your session is about to expire
← Back to Search
Amivantamab + Lazertinib + Chemotherapy for Non-Small Cell Lung Cancer (MARIPOSA-2 Trial)
MARIPOSA-2 Trial Summary
This trial will compare the effectiveness of two different cancer treatments in people with lung cancer that has continued to grow despite treatment with osimertinib.
MARIPOSA-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMARIPOSA-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MARIPOSA-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.My cancer worsened after treatment with osimertinib.I have brain metastases that are causing symptoms or getting worse.I have a history of serious heart or blood clot issues.Side effects from my previous cancer treatments have mostly gone away.I received radiotherapy for lung cancer relief less than 2 weeks ago.My lung cancer is advanced, non-squamous, and has specific EGFR mutations.I have a tumor that can be measured and hasn't been treated with radiation.My cancer has changed into small cell type.I have or had cancer spread to the lining of my brain or spinal cord, or untreated spinal cord compression.I have at least one tumor that can be measured and hasn't been treated with radiation.My lung cancer is advanced, non-squamous, and has specific EGFR mutations.I have a history of lung scarring or inflammation.I have treated brain metastases and take no more than 10mg of prednisone daily for it.
- Group 1: Arm A: LACP/ACP-L
- Group 2: Arm B: CP (Carboplatin and Pemetrexed)
- Group 3: Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed)
- Group 4: Arm A2 (Extension Cohort): ACP-L
- Group 5: Arm C2 (Extension Cohort): ACP
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any similar studies to Amivantamab that have been done in the past?
"Amivantamab was first trialled at Edinburgh Royal Hospital for Sick Children in 2002. As of now, 1043 studies have completed. 805 of these studies are ongoing, a large number of which are based in East Brunswick, New jersey."
What are Amivantamab's most popular indications?
"Amivantamab is commonly used as an initial treatment, but can also be effective for more advanced forms of thymoma, testicular cancer, neuroendocrine carcinoma, and other cancers."
What is the status of Amivantamab's FDA application?
"Amivantamab has been studied in earlier phases and has been shown to be safe and effective, so it received a score of 3."
What is the total number of active sites for this trial?
"Right now, this clinical trial is looking for participants from 32 different sites. These locations include cities such as East Brunswick, Dallas and Tucson. If you are considering participating, try and pick a location that is close to minimize travel."
Are there any vacancies in this research for people who want to participate?
"Yes, the information on clinicaltrials.gov states that this trial is still looking for patients. The trial was first posted on 11/17/2021 and was last updated on 11/9/2022. Currently, the trial has 32 locations and is looking for 600 participants."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger